These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12678728)

  • 21. Telomerase inhibitors in cancer therapy: current status and future directions.
    Incles CM; Schultes CM; Neidle S
    Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic strategies for targeting telomerase in cancer.
    Chen X; Tang WJ; Shi JB; Liu MM; Liu XH
    Med Res Rev; 2020 Mar; 40(2):532-585. PubMed ID: 31361345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the molecular design of potential anticancer agents via targeting of human telomeric DNA.
    Maji B; Bhattacharya S
    Chem Commun (Camb); 2014 Jun; 50(49):6422-38. PubMed ID: 24695755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Telomere and telomerase as targets for anti-cancer drugs].
    Ide T
    Nihon Rinsho; 2004 Jul; 62(7):1271-6. PubMed ID: 15283143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telomere and telomerase in oncology.
    Mu J; Wei LX
    Cell Res; 2002 Mar; 12(1):1-7. PubMed ID: 11942406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telomerase inhibition, oligonucleotides, and clinical trials.
    Corey DR
    Oncogene; 2002 Jan; 21(4):631-7. PubMed ID: 11850789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telomerase inhibitors: a patent review (2010-2015).
    Man RJ; Chen LW; Zhu HL
    Expert Opin Ther Pat; 2016 Jun; 26(6):679-88. PubMed ID: 27104627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telomerase inhibitors: targeting the vulnerable end of cancer?
    Kelland LR
    Anticancer Drugs; 2000 Aug; 11(7):503-13. PubMed ID: 11036953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death.
    Herbert B; Pitts AE; Baker SI; Hamilton SE; Wright WE; Shay JW; Corey DR
    Proc Natl Acad Sci U S A; 1999 Dec; 96(25):14276-81. PubMed ID: 10588696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telomere maintenance mechanisms as a target for drug development.
    Bearss DJ; Hurley LH; Von Hoff DD
    Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
    Dominick PK; Keppler BR; Legassie JD; Moon IK; Jarstfer MB
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3467-71. PubMed ID: 15177454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telomerase inhibition, telomere attrition and proliferation arrest of cancer cells induced by phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT.
    Diala I; Shiohama Y; Fujita T; Kotake Y; Demonacos C; Krstic-Demonacos M; Leva GD; Fujii M
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):407-425. PubMed ID: 32310030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telomerase inhibition as cancer therapy.
    Saretzki G
    Cancer Lett; 2003 May; 194(2):209-19. PubMed ID: 12757979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomerase inhibitors for the treatment of cancer: the current perspective.
    Perry PJ; Arnold JR; Jenkins TC
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2141-56. PubMed ID: 11772310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 6-mer photocontrolled oligonucleotide as an effective telomerase inhibitor.
    Xu Y; Ito K; Suzuki Y; Komiyama M
    J Am Chem Soc; 2010 Jan; 132(2):631-7. PubMed ID: 20014834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.
    Jafri MA; Ansari SA; Alqahtani MH; Shay JW
    Genome Med; 2016 Jun; 8(1):69. PubMed ID: 27323951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of telomerase activity by preventing proper assemblage.
    Keppler BR; Jarstfer MB
    Biochemistry; 2004 Jan; 43(2):334-43. PubMed ID: 14717587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors.
    Saraswati AP; Relitti N; Brindisi M; Gemma S; Zisterer D; Butini S; Campiani G
    Drug Discov Today; 2019 Jul; 24(7):1370-1388. PubMed ID: 31136800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.